E. Crain

发表

Platelet Aggregometry and Receptor Binding to Predict the Magnitude of Antithrombotic and Bleeding Time Effects of Clopidogrel in Rabbits

R. Rehfuss, P. Wong, M. Ogletree, 2007, Journal of cardiovascular pharmacology.

A small-molecule factor XIa inhibitor produces antithrombotic efficacy with minimal bleeding time prolongation in rabbits

P. Wong, W. Schumacher, E. Crain, 2011, Journal of Thrombosis and Thrombolysis.

Nonpeptide Factor Xa Inhibitors III: Effects of DPC423, an Orally-Active Pyrazole Antithrombotic Agent, on Arterial Thrombosis in Rabbits

P. Lam, R. Knabb, R. Wexler, 2002, Journal of Pharmacology and Experimental Therapeutics.

Arterial antithrombotic and bleeding time effects of apixaban, a direct factor Xa inhibitor, in combination with antiplatelet therapy in rabbits

P. Wong, E. Crain, C. Watson, 2008, Journal of thrombosis and haemostasis : JTH.

Apixaban, an oral direct factor Xa inhibitor, inhibits human clot-bound factor Xa activity in vitro

P. Wong, J. Luettgen, W. Schumacher, 2009, Thrombosis and Haemostasis.

Discovery of 4-aryl-7-hydroxyindoline-based P2Y1 antagonists as novel antiplatelet agents.

P. Lam, Hong Shen, R. Rehfuss, 2014, Journal of medicinal chemistry.

Discovery of diarylurea P2Y(1) antagonists with improved aqueous solubility.

P. Lam, R. Rehfuss, D. Seiffert, 2013, Bioorganic & medicinal chemistry letters.

In vitro, antithrombotic and bleeding time studies of BMS-654457, a small-molecule, reversible and direct inhibitor of factor XIa

D. Seiffert, A. Rendina, M. Harpel, 2015, Journal of Thrombosis and Thrombolysis.

Discovery of a Potent Parenterally Administered Factor XIa Inhibitor with Hydroxyquinolin-2(1H)-one as the P2' Moiety.

S. Sheriff, D. Seiffert, J. Bozarth, 2015, ACS Medicinal Chemistry Letters.

Metabolism, pharmacokinetics and pharmacodynamics of the factor Xa inhibitor apixaban in rabbits

K. He, B. Xin, Donglu Zhang, 2009, Journal of Thrombosis and Thrombolysis.

Nonpeptide factor Xa inhibitors II. Antithrombotic evaluation in a rabbit model of electrically induced carotid artery thrombosis.

R. Knabb, A. Slee, R. Wexler, 2000, The Journal of pharmacology and experimental therapeutics.

Discovery of Milvexian, a High-Affinity, Orally Bioavailable Inhibitor of Factor XIa in Clinical Studies for Antithrombotic Therapy.

Michael A. Galella, S. Sheriff, A. Mathur, 2021, Journal of medicinal chemistry.

Discovery of a High Affinity, Orally Bioavailable Macrocyclic FXIa Inhibitor with Antithrombotic Activity in Preclinical Species.

P. Lam, S. Sheriff, A. Mathur, 2020, Journal of medicinal chemistry.

Novel phenylalanine derived diamides as Factor XIa inhibitors.

P. Lam, P. Morin, D. Seiffert, 2016, Bioorganic & medicinal chemistry letters.

Calibration and validation of the rabbit model of electrolytic‐mediated arterial thrombosis against the standard‐of‐care anticoagulant apixaban

P. Wong, E. Crain, 2022, Pharmacology research & perspectives.

Favorable therapeutic index of the direct factor Xa inhibitors, apixaban and rivaroxaban, compared with the thrombin inhibitor dabigatran in rabbits

B. Xin, P. Wong, E. Crain, 2009, Journal of thrombosis and haemostasis : JTH.

Razaxaban, a direct factor Xa inhibitor, in combination with aspirin and/or clopidogrel improves low-dose antithrombotic activity without enhancing bleeding liability in rabbits

P. Lam, R. Knabb, R. Wexler, 2007, Journal of Thrombosis and Thrombolysis.

Antithrombotic actions of selective inhibitors of blood coagulation factor Xa in rat models of thrombosis.

P. Wong, E. Crain, C. Watson, 1996, Thrombosis research.

Clopidogrel versus prasugrel in rabbits

R. Rehfuss, P. Wong, W. Schumacher, 2008, Thrombosis and Haemostasis.

Nonpeptide factor Xa inhibitors: I. Studies with SF303 and SK549, a new class of potent antithrombotics.

R. Knabb, R. Wexler, P. Wong, 2000, The Journal of pharmacology and experimental therapeutics.

Discovery of a Parenteral Small Molecule Coagulation Factor XIa Inhibitor Clinical Candidate (BMS-962212).

P. Lam, S. Sheriff, A. Mathur, 2017, Journal of medicinal chemistry.

Apixaban, an oral, direct and highly selective factor Xa inhibitor: in vitro, antithrombotic and antihemostatic studies

P. Lam, R. Knabb, B. Xin, 2008, Journal of thrombosis and haemostasis : JTH.

Potent, Orally Bioavailable and Efficacious Macrocyclic Inhibitors of Factor XIa. Discovery of Pyridine-Based Macrocycles Possessing Phenylazole Carboxamide P1 Groups.

P. Lam, S. Sheriff, A. Mathur, 2019, Journal of medicinal chemistry.

Milvexian, an orally bioavailable, small‐molecule, reversible, direct inhibitor of factor XIa: In vitro studies and in vivo evaluation in experimental thrombosis in rabbits

D. Gordon, W. R. Ewing, J. Bozarth, 2021, Journal of thrombosis and haemostasis : JTH.

The P2Y1 receptor antagonist MRS2500 prevents carotid artery thrombosis in cynomolgus monkeys

P. Wong, E. Crain, C. Watson, 2016, Journal of Thrombosis and Thrombolysis.

In Vitro and In Vivo Evaluation of a Small-Molecule APJ (Apelin Receptor) Agonist, BMS-986224, as a Potential Treatment for Heart Failure

P. Gargalovic, M. Bouvier, D. Gordon, 2021, Circulation. Heart failure.

Favorable therapeutic index of the direct factor Xa inhibitors, apixaban and rivaroxaban, compared with the thrombin inhibitor dabigatran in rabbits

E. Crain, C. Watson, Baomin Xin, 2009, Journal of thrombosis and haemostasis : JTH.

Discovery of a Potent Parenterally Administered Factor XIa Inhibitor with Hydroxyquinolin-2(1H)-one as the P2' Moiety.

S. Sheriff, D. Seiffert, J. Bozarth, 2015, ACS medicinal chemistry letters.